Skip to main content
. 2021 Feb 15;14:25. doi: 10.1186/s13045-020-01020-y

Table 2.

Overall best response among all treated patients by BICR

Response Daratumumab 16 mg/kg (n = 32)
No. % 95% CI
ORR 8 25.0 11.5–43.4
Clinical benefit rate (CR + PR + stable disease) 14 43.8 26.4–62.3
CR 0 0
PR 8 25.0
Stable disease 6 18.8
PD 14 43.8
NE 4 12.5

BICR, blinded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response